Results 41 to 50 of about 3,014 (182)

A Streamlined, Green, and Sustainable Synthesis of the Anticancer Agent Erdafitinib

, 2023
Erdafitinib, an anticancer drug, was synthesized in a three-step two-pot sequence involving ppm levels of Pd catalyst run under aqueous micellar conditions enabled by a biodegradable surfactant.
Vani Singhania (4345570), Maya Reamey (16030719), Emile Morin, Bruce H. Lipshutz, Chandler B. Nelson (16030716), Bruce H. Lipshutz (1330881), Chandler B. Nelson, Emile Morin (16030722), Rahul D. Kavthe (2297344), Rahul D. Kavthe, Maya Reamey, Vani Singhania   +11 more
core   +1 more source

The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors

Medicinal Research Reviews, EarlyView.
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti, Camilla Tavani, Elena Somenza, Nicolas Tassone, Antonio d'Amati, Marta Turati, Roberto Ronca   +6 more
wiley   +1 more source

Australian Practical Guide on the Management of Muscle‐Invasive Bladder Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Australia's management of muscle‐invasive bladder cancer is evolving, with increased use of perioperative therapy and emerging immunotherapies. However, challenges such as cisplatin ineligibility, limited access, and costs persist. Expanding bladder‐sparing approaches, precision medicine, and integrated care pathways will be key to improving outcomes ...
Dickon Hayne, Shomik Sengupta, Alison Y. Zhang, Niara Oliveira, Manish I. Patel, Ian Vela, Ian D. Davis   +6 more
wiley   +1 more source

A luminal non‐coding RNA‐based genomic classifier confirms favourable outcomes in patients with clinically organ‐confined bladder cancer treated with radical cystectomy

BJU International, Volume 135, Issue 4, Page 648-656, April 2025.
Objective To further evaluate a genomic classifier (GC) in a cohort of patients undergoing radical cystectomy (RC), as long non‐coding RNA (lncRNA)‐based genomic profiling has suggested utility in identifying a distinct tumour subgroup corresponding to a favourable prognosis in patients with bladder cancer.
Joep J. de Jong, James A. Proudfoot, Siamak Daneshmand, Robert S. Svatek, Vikram Narayan, Ewan A. Gibb, Elai Davicioni, Shreyas Joshi, Aaron Dahmen, Roger Li, Brant A. Inman, Paras Shah, Iftach Chaplin, Jonathan Wright, Yair Lotan   +14 more
wiley   +1 more source

Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer

Cancer Science, EarlyView.
Integrated analysis of 445 bladder cancers showed that HER2 membrane expression and ERBB2 amplification are distinct features. HER2 expression overlapped with NECTIN4 expression, whereas ERBB2 amplification was enriched in the LumU subtype and associated with poor prognosis.
Kensuke Hirosuna, Kazuki Nishimura, Moritoshi Sakamoto, Satoshi Tokushige, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Takeshi Tsutsumi, Ryoichi Maenosono, Takuya Tsujino, Masahiko Ajiro, Haruhito Azuma, Akihide Yoshimi, Kazumasa Komura   +13 more
wiley   +1 more source

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib [PDF]

, 2019
ImportanceWhen a novel drug is granted accelerated approval, both its on-label and off-label uses must be taken into account.ObjectivesTo estimate the potential upper bound of off-label use of erdafitinib to treat advanced cancer with fibroblast growth ...
Haslam, Alyson, Gill, Jennifer, de Almeida Carvalho, Lelia Maria, Prasad, Vinay, de Oliveira Sapori Avelar, Sandra   +4 more
core   +1 more source

Case report: Slipped capital femoral epiphysis: a rare adverse event associated with FGFR tyrosine kinase inhibitor therapy in a child

Frontiers in Oncology
We report a case of slipped capital femoral epiphysis (SCFE), an on target skeletal toxicity of a pan-FGFR TKI inhibitor, erdafitinib. A 13-year-old boy was diagnosed to have an optic pathway/hypothalamic glioma with signs of increased intracranial ...
Meziane Brizini, Meziane Brizini, Tina Drimes, Catherine Bourne, Jessica Streilein, Annie Drapeau, Jens Wrogemann, Lori Anne Archer, Marc Del Bigio, Magimairajan Issai Vanan, Magimairajan Issai Vanan, Magimairajan Issai Vanan   +11 more
doaj   +1 more source

Immune platelet transfusion refractoriness associated with anti‐CD36 alloimmunisation in a Brazilian patient with platelet CD36 deficiency

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Immune platelet transfusion refractoriness (PTR) is usually mediated by anti‐HLA class I antibodies; immunisation against CD36 (platelet glycoprotein IV [GPIV]) is relatively rare. Platelet CD36 deficiency shows marked ethnic variability and is seldom reported in admixed Latin American populations.
Rayane Dayse Alves Conserva, Luiz Frederico Bezerra Honorato Junior, Ana Paula Hitomi Yokoyama, Thiago Henrique Costa, Luis Henrique Cardoso Fedeli, Ana Cynira Franco Marret, Eduardo Perez Bastos, Fabio Pires de Souza Santos, Luana Nobrega Costa, Livia Chiosini de Nadai, Carolina Bonet‐Bub, Jose Mauro Kutner   +11 more
wiley   +1 more source

Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR‐Altered Bladder Cancer

Advanced Science
Fibroblast growth factor receptor (FGFR) family aberrations are common in urothelial cancer. The FGFR tyrosine kinase inhibitor erdafitinib has been approved for locally advanced or metastatic urothelial cancer with FGFR2/3 alterations.
Huayuan Zhao, Xincheng Gao, Yangkai Jiang, Yanchao Yu, Liang Wang, Jiayin Sun, Miao Wang, Xing Xiong, Chao Huang, Hui Zhang, Guosong Jiang   +10 more
doaj   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling‐Veninga, Katja Taxis, Frank G. A. Jansman   +5 more
wiley   +1 more source